Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.
about
Applications of targeted proteomics in systems biology and translational medicineDrug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Emerging proteomic technologies for elucidating context-dependent cellular signaling events: A big challenge of tiny proportionsAn inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cellsEvaluating melanoma drug response and therapeutic escape with quantitative proteomicsEvaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides.Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells.The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy.A Timely Shift from Shotgun to Targeted Proteomics and How It Can Be Groundbreaking for Cancer Research.QconCATs: design and expression of concatenated protein standards for multiplexed protein quantification.Oncogenic KRAS and BRAF Drive Metabolic Reprogramming in Colorectal Cancer.Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer.Knockdown of REGγ inhibits the proliferation and migration and promotes the apoptosis of multiple myeloma cells by downregulating NF-κB signal pathway.Soluble and Cell-Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma.
P2860
Q26852271-BCEBD99A-A856-4153-9CF1-BDCB41164F91Q27692033-C2D648F5-05BC-4462-A238-410993C1D957Q28081956-DCFD5F53-84A2-4169-AEA4-F7D49F0E95D4Q28486021-E6C49A9A-4E4E-40FE-8E47-363F420B2E31Q33850665-3F4D7783-DA5E-4741-9964-73FB233BAD60Q35579916-5FEA9F93-3307-46E8-95A6-8000468634F1Q36373537-89705512-0C4F-413E-8FEB-2B90BA1DCF44Q37513374-507861B5-940D-4112-A13B-8527BF96FFB4Q37651691-A588DC11-F8FF-4404-A038-63DDB3304479Q38024638-6CA47A32-3D60-450D-A5B6-2575F98C9B35Q38762520-85FA456F-3B44-46A7-8196-60A0B1125BE9Q47374639-0DC173DD-5EA0-4EA5-953B-46291E2C17DFQ47666357-C32C4F26-6212-4A36-8A22-7F4BE2C12B65Q55091606-4CE04E63-B360-4573-9A7B-B7B85750E4AE
P2860
Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.
@ast
Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.
@en
type
label
Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.
@ast
Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.
@en
prefLabel
Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.
@ast
Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.
@en
P2093
P2860
P356
P1476
Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.
@en
P2093
Christopher Cubitt
Danielle Yarde
Elizabeth R Remily-Wood
Jin Q Cheng
John M Koomen
Kelly Boucher
Kenneth H Shain
Linda Mathews
P2860
P304
M110.005520
P356
10.1074/MCP.M110.005520
P577
2011-08-16T00:00:00Z